According to FactSet, Third Point already owned about 450,000 Amgen shares, a stake worth roughly $64.8 million. [...] Point said Amgen Inc., which makes a range of drugs for arthritis, anemia and other diseases, is not given enough credit for its existing drugs or the potential of its pipeline.